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Objectives The ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary
Treatment-4) platelet substudy aimed to determine the relevance of high on-clopidogrel treatment platelet reac-
tivity (HPR) in non–ST-segment elevation myocardial infarction patients that received abciximab with unfraction-
ated heparin (UFH) or bivalirudin during percutaneous coronary intervention (PCI).
Background In patients undergoing PCI, HPR has been linked to a higher risk for ischemic events. The influence of HPR on
clinical outcomes may differ with regard to the adjunctive antithrombotic treatment administered. In ISAR-
REACT 4, bivalirudin treatment showed similar efficacy profiles as compared to abciximab with UFH. The impact
of HPR on clinical outcomes in abciximab with UFH versus bivalirudin treated non–ST-segment elevation myocar-
dial infarction patients has never been investigated specifically.
Methods A total of 564 patients (274 in abciximab/UFH group vs. 290 in bivalirudin group) were enrolled in this study.
Presence or absence of HPR following clopidogrel loading was determined by platelet function testing on a Mul-
tiplate analyzer (Verum Diagnostica, Munich, Germany). Per study group and stratified in HPR and no-HPR pa-
tients, the 30-day incidence of a combined efficacy endpoint (death, myocardial infarction, urgent target vessel
revascularization) was determined.
Results For abciximab with UFH, the incidence of the efficacy endpoint was similar in HPR versus no-HPR patients (9.4%
vs. 6.7%; odds ratio: 1.4; 95% confidence interval: 0.6 to 3.5; p  0.43). For bivalirudin, the incidence of the effi-
cacy endpoint was significantly higher in HPR versus no-HPR patients (22.0% vs. 5.0%; odds ratio: 5.4; 95% con-
fidence interval: 2.4 to 12.1; p  0.0001).
Conclusions For patients with a risk profile similar to the subjects enrolled in this platelet substudy, the impact of HPR on clinical
outcomes may depend on the type of adjunctive antithrombotic therapy used during PCI. Further investigations are
warranted to clarify whether assessment of platelet function may help tailoring antithrombotic therapy during PCI.
(Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome [ISAR-REACT 4];
NCT00373451) (J Am Coll Cardiol 2012;60:369–77) © 2012 by the American College of Cardiology Foundation
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treatment is not uniform (1) and
a high on-clopidogrel treatment
platelet reactivity (HPR) has
been linked to an increased risk
for ischemic events in numerous
See page 378
studies (2–5) as well as their
meta-analyses (6). Results from
recently reported randomized tri-
als such as the GRAVITAS
(Gauging Responsiveness With
A VerifyNow Assay: Impact On
Thrombosis And Safety) trial (7)
and the TRIGGER-PCI (Testing
platelet Reactivity In patients
underGoing elective stent place-
ment on clopidogrel to Guide
alternative thErapy with pRasu-
grel) trial (8) as well as data from
the ADAPT-DES (Assessment
of Dual AntiPlatelet Therapy
with Drug-Eluting Stents) regis-
try (9) suggested that the exis-
tence of HPR and switching pa-
tients to intensified treatment
regimens may play a more prominent role in acute coronary
syndrome (ACS) patients undergoing urgent percutaneous
coronary intervention (PCI) procedures and may only play a
minor role in stable patients undergoing elective PCI.
Along with a dual antiplatelet treatment consisting of
aspirin and a P2Y12 receptor inhibitor such as clopidogrel,
different adjunctive antithrombotic treatment regimens are
being used in the setting of PCI (10). Identifying the best
adjunctive treatment approach for PCI treated patients in
different clinical settings ranging from stable coronary artery
disease (CAD) patients to CAD patients presenting with
ST-segment elevation myocardial infarction (STEMI) has
been the focus of extensive research during the last decades
(11–15). Just recently, we reported the results of the
ISAR-REACT 4 (Intracoronary Stenting and Antithrom-
botic Regimen: Rapid Early Action for Coronary Treat-
ment 4) trial that aimed to compare the safety and efficacy
of combined abciximab with unfractionated heparin (UFH)
treatment versus bivalirudin treatment alone in clopidogrel
treated non–ST-segment elevation myocardial infarction
(NSTEMI) patients undergoing urgent PCI (16). When
comparing both treatment groups, the cumulative incidence
of the combined efficacy endpoint (death, any recurrent
myocardial infarction [MI], urgent target-vessel revascular-
ization [TVR]) was similar during a 30-day follow-up
period. However, bivalirudin was associated with a mark-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AU  aggregation unit
CAD  coronary artery
disease
CI  confidence interval
HPR  high on-clopidogrel
treatment platelet
reactivity
LPR  low platelet
reactivity
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TVR  target vessel
revascularization
UFH  unfractionated
heparinedly reduced risk of major bleeding.Keeping in mind the different pharmacological properties
of these 2 treatment approaches with bivalirudin as a direct
and rapidly acting thrombin inhibitor that also shows
antiplatelet action (17) and with UFH inhibiting free
thrombin indirectly and the glycoprotein IIb/IIIa inhibitor
abciximab being a potent antiplatelet agent, presence or
absence of HPR in clopidogrel treated NSTEMI patients
may have a differential impact on the risk for post-PCI
ischemic events. With regard to this, the prognostic value of
HPR in relation to different adjunctive antithrombotic
treatment regimens has never been investigated specifically.
Thus, the objective of the ISAR-REACT 4 platelet
substudy was to determine the relevance of HPR in
NSTEMI patients that received either combined abciximab
with UFH or bivalirudin treatment during the PCI
procedure.
Methods
Study population and design. All patients recruited for
this platelet substudy were part of the ISAR-REACT 4 trial
(16) that aimed to compare the clinical outcome of
NSTEMI patients receiving either abciximab with UFH or
bivalirudin treatment during PCI. The present platelet
substudy included a cohort of 564 patients with platelet
function measurements available for the index PCI proce-
dure. The inclusion and exclusion criteria for this study were
identical to those of the ISAR-REACT 4 trial (16). In
brief, the primary trial enrolled patients with the following
inclusion criteria: an accelerating pattern of angina pectoris
or angina lasting 20 min or recurrent episodes of angina
(either at rest or during minimal exertion) within the
preceding 48 h; levels of cardiac biomarkers (troponin T or
creatine kinase-myocardial band isoenzymes) that were
above the upper limit of normal range; and coronary
stenoses requiring urgent PCI. A detailed description of
exclusion criteria is listed elsewhere (16).
All patients included here were recruited at 2 participat-
ing centers of the multicenter ISAR-REACT 4 trial. These
centers were the Deutsches Herzzentrum München and the
Klinikum rechts der Isar (Technische Universität München,
Munich, Germany). A flow chart of the study population
showing all patients enrolled in these 2 centers (with and
without platelet function results available) is illustrated in
Figure 1. Within both study groups all patients received a
single high loading dose of 600 mg of clopidogrel and 500
mg aspirin i.v. in preparation for the PCI procedure.
Post-interventional antiplatelet treatment consisted of
clopidogrel 75 mg twice daily for the remainder of the
hospitalization up to 3 days, followed by 75 mg/day. The
recommended duration of clopidogrel treatment was 12
months. Aspirin 100 mg twice daily was recommended for
an indefinite period. Platelet function testing was performed
instantaneously before PCI, after clopidogrel loading, and
prior to the administration of any study drug.
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bolus of 0.25 mg abciximab as well as a bolus dose of 70
units UFH per kilogram body weight, followed by a
continuous infusion of 0.125 g abciximab per kilogram
ody weight per minute for 12 h. Patients in the bivalirudin
roup were assigned to a bolus dose of 0.75 mg per kilogram
ivalirudin, followed by a continuous infusion of 1.75 mg
er kilogram per hour during PCI. The study protocol was
pproved by the institutional ethics committee and all
atients gave written informed consent before entering the
tudy.
lood sampling and platelet function testing. Whole
lood for platelet function testing on the Multiplate ana-
yzer (Verum Diagnostica, Munich, Germany) was obtained
n the cath lab from the arterial sheath of all patients directly
efore PCI and prior to the administration of study drug
reatment. Blood was placed in 4.5-ml plastic tubes con-
aining the anticoagulant lepirudin (25 g/ml; Refludan,
ynabyte, Munich, Germany). The adenosine diphos-
hate–induced platelet aggregation was assessed. Details of
his method have been reported previously (3,18). Aggre-
ation measured on the Multiplate device is quantified as
rea under the curve of aggregation units (AU) (area under
he curve  AU  min). All material used for platelet
unction testing was obtained from the manufacturer. Dur-
ng the course of the ISAR-REACT 4 trial, patients for this
latelet substudy were enrolled at the core times of the
entral laboratory and not at night or outside the core times,
hich was due to logistic reasons.
tudy endpoints and definitions. The primary outcome
easure of this platelet substudy was the pre-specified
Figure 1 Study Flow Chart
Study flow of the ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Reg-
imen: Rapid Early Action for Coronary Treatment 4) platelet substudy including
564 non–ST-segment elevation myocardial infarction patients. HPR  high
platelet reactivity; PFT  platelet function testing; UFH  unfractionated
heparin.ombined efficacy endpoint of the ISAR-REACT 4 trial d16), which was defined as a composite of death, MI, or
rgent TVR at 30 days after PCI. To allow an overview,
esults for this combined endpoint are reported for all
atients (with and without platelet function results avail-
ble) recruited in the 2 participating centers of this platelet
ubstudy.
For the patients within the platelet substudy cohort,
resence or absence of HPR was determined per study
roup. The definition of HPR (468 AUmin) was based
n prior studies (3,19) and the consensus document (4) of
he Working Group on High On-Treatment Platelet Re-
ctivity. We also assessed the incidence of death, MI, TVR,
arge MI, and definite stent thrombosis in the 2 study
roups for HPR and no-HPR patients. Definitions of the
schemic endpoints are identical to the definitions used in
he ISAR-REACT 4 trial and have been summarized
lsewhere (16). In addition, we report on the incidence of
hrombolysis In Myocardial Infarction (TIMI) major
leeding per study group in patients with versus without an
nhanced response ( low platelet reactivity [LPR]) to
lopidogrel. LPR (AU  min 188) was defined as
reviously described (19).
tatistical analysis. Variables are presented as mean SD,
umbers (percentages), or median with interquartile range.
ategorical variables were compared using chi-square test.
olmogorov-Smirnov test was used to check for normal
istribution of continuous data. Platelet function data were
on-normally distributed and were compared across groups
ith 2-sided unpaired Wilcoxon test. Normally distributed
ontinuous data were compared across 2 groups with
-sided unpaired t test. We also tested for interactions
egarding the combined efficacy endpoint: 1) between study
reatment arm and availability of platelet function testing;
nd 2) between study treatment arm and platelet aggrega-
ion. Interaction was tested in a Cox proportional hazards
odel. Kaplan-Meier curves were plotted to illustrate the
umulative incidence of the combined efficacy endpoint per
tudy group and with regard to presence or absence of HPR.
ll analyses were performed using the software package
-PLUS (TIBCO Software Inc., Palo Alto, California).
or all statistical analyses a p value 0.05 was considered
tatistically significant.
esults
tudy flow and study population. From the entire multi-
enter study population (1,721 patients) of the ISAR-
EACT 4 trial, 1,195 patients were enrolled in the 2
articipating centers of platelet substudy. As outlined in
he study flow chart (Fig. 1), whole blood for platelet
unction testing was available in 564 patients (47.2%),
ho constitute the platelet substudy cohort. No blood for
latelet function testing was available in the remaining
31 patients (52.8%). This is due to the fact that the
evice for platelet function testing was not available
uring the early course of the trial (91 patients were
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and also because patients for the platelet substudy were
enrolled at the core times of the central laboratory and
not at night or outside the core times. Some baseline and
procedural characteristics differed between patients with
(n  564) and without (n  631) platelet function results
vailable (Online Tables 1 and 2). Of note, patients
utside the platelet substudy cohort had a lower ejection
raction and more often a history of prior MI.
The 30-day combined efficacy endpoint (death, MI,
rgent TVR) occurred in 151 (13%) patients of the entire
ohort (n 1,195) of patients enrolled in the 2 participating
enters. For patients included in the platelet substudy (n 
64), the combined efficacy endpoint occurred in 54 (9.6%)
atients. The cumulative incidence of this endpoint did not
iffer between patients (n  274) treated with abciximab
lus UFH as compared with patients (n 290) treated with
ivalirudin (21 [7.7%] vs. 33 [11.4%] patients, respectively;
 0.13). For patients not included in the platelet substudy
n  631), the combined efficacy endpoint occurred in 97
15.0%) patients. The cumulative incidence of this endpoint
id not differ between patients (n  324) treated with
bciximab plus UFH as compared with patients (n  307)
reated with bivalirudin (52 [16.0%] vs. 45 [14.7%] patients,
espectively; p  0.63). No significant interaction was
bserved between study treatment arm and availability of
latelet function testing regarding the combined efficacy
ndpoint (p for interaction  0.12).
latelet substudy cohort. The mean age of patients (n 
64) included in this cohort was 67.7 years and the
roportion of women was 22% (n  126). Baseline charac-
Baseline Characteristics of the PatientsTable 1 Baseline Characteristics of the Pat
Characteristic
Abc
Age, yrs
Female
Body mass index, kg/m2
Diabetes mellitus
Any
Insulin-dependent
Arterial hypertension
Hypercholesterolemia
Current smoker
No. of diseased coronary vessels
1
2
3
Previous myocardial infarction
Previous percutaneous coronary intervention
Previous coronary artery bypass surgery
Glomerular filtration rate, ml/min
Troponin T, g/l 0
Left ventricular ejection fraction,* %
Values are mean SD, median (interquartile range), or n (%). *Ejection
group and 250 in the bivalirudin group.
UFH  unfractionated heparin.eristics of the study population including age, gender, and
ardiovascular risk factors were similar between the 2 study
reatment arms (Table 1). Angiographic and procedural
haracteristics (Table 2) of the study population were
imilar between both treatment arms as well except for the
tenosis after the procedure, which was slightly higher in the
ivalirudin group. Clinical follow-up at 30 days was com-
leted (100%) for all 564 patients.
The adenosine diphosphate–induced platelet aggrega-
ion values (median [interquartile range]) at the time
oint of the PCI procedure and following loading with
00 mg of clopidogrel were similar between the 2
reatment groups (305 [169 to 597] AU  min in the
bciximab with UFH group vs. 329 [197 to 582] AU 
in in the bivalirudin group; p  0.31). In the entire
latelet substudy cohort a total of 205 patients (36%)
howed an HPR at the time point of the PCI procedure.
he proportion of patients with HPR was comparable
etween the 2 study groups (96 [35.0%] in the abciximab
ith UFH group vs. 109 [37.6%] patients in the bivali-
udin group; p  0.53).
linical outcome data per group and HPR. In the
bciximab with UFH group the incidence of the combined
fficacy endpoint was similar in HPR versus no-HPR
atients (9.4% vs. 6.7%; odds ratio [OR]: 1.4; 95% confi-
ence interval [CI]: 0.6 to 3.5; p  0.43) (Fig. 2A). For
ivalirudin treated patients, the incidence of the combined
fficacy endpoint was significantly higher in HPR versus
o-HPR patients (22.0% vs. 5.0%; OR: 5.4; 95% CI: 2.4 to
2.1; p  0.0001) (Fig. 2B). A significant interaction was
bserved between study treatment arm and platelet aggrega-
b Plus UFH
274)
Bivalirudin
(n  290) p Value
 11.4 67.6 10.1 0.88
(24.0) 60 (21.0) 0.33
 4.4 27.9 4.2 0.99
(32.0) 88 (30.0) 0.65
(9.9) 30 (10.3) 0.85
(88.3) 262 (90.3) 0.44
(74.0) 196 (68.0) 0.11
(23.0) 60 (21.0) 0.44
0.78
(15.0) 49 (16.9)
(21.5) 58 (20.0)
(63.5) 183 (63.1)
(21.0) 51 (18.0) 0.33
(42.0) 102 (35.0) 0.12
(14.2) 40 (13.8) 0.88
 34 87 31 0.68
03–0.29) 0.06 (0.03–0.24) 0.81
 11.5 51.0 11.7 0.95
n data were available for 496 patients: 246 in the abciximab plus UFHients
ixima
(n 
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tion  0.037). Table 3 shows the entire clinical outcome data
n the 2 study groups according to the presence or absence of
PR. For abciximab treated patients, none of the ischemic
vents investigated showed significant differences between
PR and no-HPR patients (Table 3). For bivalirudin treated
atients, a significantly higher risk for any recurrent MI, death,
r any recurrent MI, as well as large MI, was observed in HPR
ersus no-HPR patients (Table 3).
In the entire study cohort (n  564) and regardless of
hether bivalirudin or abciximab plus UFH was adminis-
ered during the PCI procedure, the incidence of the
ombined efficacy endpoint was significantly higher in HPR
n  205) versus no-HPR (n  359) patients (16.1% vs.
5.8%; OR: 3.1; 95% CI: 1.7 to 5.5; p  0.0001). Major
bleeding (according to TIMI criteria) occurred in 5 patients
(5 of 274  1.8%) in the abciximab with UFH group and
events were numerically higher in patients exhibiting a
status of LPR (AUmin188) as compared with patients
without LPR (4 events [4.9%] in 82 patients vs. 1 event
[0.5%] in 192 patients, respectively; p [Fisher exact] 
0.06). In the bivalirudin group, only 1 (1 of 290  0.3%)
Infarct-Related Lesion Characteristics and TypeTable 2 Infarct-Related Lesion Characteristi
Characteristic
Target vessel
Left main coronary artery
Left anterior descending coronary artery
Left circumflex coronary artery
Right coronary artery
Venous bypass graft
Complex (type B2 or C) lesions
TIMI flow grade before intervention
0
1
2
3
Lesion length, mm
Vessel size, mm
Stenosis before procedure, % of luminal diameter
Maximal balloon pressure, atm
Balloon-to-vessel ratio
Type of intervention
Placement of drug-eluting stent
Placement of bare-metal stent
Balloon angioplasty
Length of stented segment
Stenosis after procedure, % of luminal diameter
TIMI flow grade after intervention
0
1
2
3
Values are mean  SD or n (%).
TIMI  Thrombolysis In Myocardial Infarction; UFH  unfractionateajor bleeding event occurred in a patient without LPR. hiscussion
he ISAR-REACT 4 platelet substudy is the first study
hat specifically aimed to investigate and to compare the
rognostic value of HPR in NSTEMI patients that either
eceived adjunctive antithrombotic treatment with com-
ined abciximab plus UFH or bivalirudin during the PCI
rocedure. To the best of our knowledge, this study is also
he first to evaluate the prognostic value of clopidogrel
esponse testing in a cohort of NSTEMI patients that was
rimarily recruited and treated in a randomized and well-
ontrolled fashion within a large-scale clinical trial investi-
ating the value of different adjunctive antithrombotic
reatment options for patients undergoing urgent PCI. Key
esults of this platelet substudy can be summarized as the
ollowing: The prognostic value of HPR determined by
eriprocedural platelet function testing for predicting ische-
ic events in NSTEMI patients may depend on the
djunctive antithrombotic agent administered. Whereas the
resence of HPR in bivalirudin treated patients was relevant
nd predictive for the occurrence of early ischemic events,
resence of HPR in abciximab with UFH treated patients
nterventiond Types of Intervention
ximab Plus UFH
(n  274)
Bivalirudin
(n  290) p Value
0.86
15 (5.5) 15 (5.2)
104 (38.0) 118 (40.7)
65 (23.7) 64 (22.1)
74 (27.0) 81 (27.9)
16 (5.8) 12 (4.1)
229 (83.6) 259 (89.3) 0.05
0.78
45 (16.4) 51 (17.6)
16 (5.8) 21 (7.2)
68 (24.8) 76 (26.2)
145 (52.9) 142 (49.0)
17.8 9.7 18.6 11.2 0.38
3.0 0.6 3.0 0.6 0.75
75 16 77 16 0.15
15 3 15 3 0.18
1.1 0.1 1.1 0.1 0.72
0.13
256 (93.4) 264 (91.0)
2 (0.7) 9 (3.1)
16 (5.8) 17 (5.9)
29 12 30 15 0.27
13 10 15 15 0.04
0.47
1 (0.4) 4 (1.4)
2 (0.7) 4 (1.4)
10 (3.7) 8 (2.8)
261 (95.3) 274 (94.5)
in.s of Ics an
Abciad little relevance in this regard. Present data suggest that
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HPR With Bivalirudin or Abciximab in NSTEMI July 31, 2012:369–77stronger platelet inhibition, such as provided by abciximab,
is beneficial in NSTEMI patients who still have HPR after
600 mg clopidogrel loading. This finding is in line with
Figure 2 Cumulative Incidence of the
Combined Efficacy Endpoint
The cumulative incidence of the combined efficacy endpoint (death, MI, or
urgent TVR) in the 30 days after PCI is shown per study group. Odds ratios
(ORs) reported are based on raw endpoint counts and Kaplan-Maier curves are
shown for illustrative purposes. Panel A shows the incidence of the endpoint
in the abciximab with UFH group in patients with HPR (red line) and without
HPR (black line). Panel B shows the incidence of the endpoint in the bivaliru-
din group in patients with HPR (red line) and without HPR (black line). CI 
confidence interval; HPR  high platelet reactivity; MI  myocardial infarction;
TVR  target vessel revascularization; UFH  unfractionated heparin.
Clinical Outcomes per Study GroupTable 3 Clinical Outcomes per Study Group
Abciximab Plus UFH
Outcome HPR (n  96) No HPR (n 
Efficacy endpoint: death, MI, urgent TVR 9 (9.4) 12 (6.7
Death 1 (1.0) 3 (1.7
Any recurrent MI 8 (8.3) 11 (6.2
Death or any recurrent MI 9 (9.4) 12 (6.7
Large MI 4 (4.2) 5 (2.8
Urgent TVR 0 (0.0) 1 (0.6
Definite ST 0 (0.0) 1 (0.6Values are n (%).
HPR  high platelet reactivity; MI  myocardial infarction; ST  stent thrombosis; TVR  target vesseprior studies that reported on a beneficial effect of glyco-
protein IIb/IIIa inhibitors in PCI treated patients showing
HPR on clopidogrel treatment (20,21).
Of note, not all patients of the ISAR-REACT 4 trial
were included in this platelet substudy and the overall event
rates of patients with and without platelet function testing
results available differed with event rates being numerically
higher in patients without platelet function testing. This
could be explained by the circumstance that blood for
testing was only obtained during the core time of the 2
participating centers of this platelet substudy. As a conse-
quence, the platelet substudy cohort must be considered as
a lower-risk cohort when compared with the entire study
population, as patients enrolled outside core time or even at
night generally constitute a high-risk group of patients with
higher event rates (22). This is also reflected in differences of
baseline characteristics when comparing patients with and
without platelet function testing available.
In the entire ISAR-REACT 4 study cohort (16), the
pre-specified efficacy endpoint did not differ between abcix-
imab with UFH versus bivalirudin treated patients and for
all ischemic endpoint studied both treatment options
showed similar efficacy profiles. Importantly, the overall
event rates for the same combined efficacy endpoint did not
differ between the 2 study groups within this platelet
substudy cohort as well. Further on, strengths of the present
study cohort include the circumstance that both study
groups were comparable in terms of their baseline, their
procedural, and their platelet function characteristics. These
observations are important and set the basis for further
stratifying patients according to the presence or absence of
HPR with the aim of investigating the ischemic risk within
the distinct subgroups.
Whereas the proportion of HPR patients (about 35% per
group) was similar between both study groups, the ischemic
event rates, however, showed a completely different pattern.
Finding only little differences for HPR and no-HPR pa-
tients within the abciximab/UFH group, the observed
differences in the bivalirudin arm are remarkable and war-
rant further discussion. On the one hand, no-HPR patients
(about two-thirds of patients) in the bivalirudin arm showed
the lowest event rate from all subgroups investigated here
Bivalirudin
p Value HPR (n  109) No HPR (n  181) p Value
0.43 24 (22.0) 9 (5.0) 0.001
0.67 1 (0.9) 1 (0.6) 0.72
0.50 22 (20.2) 8 (4.4) 0.001
0.43 23 (21.1) 9 (5.0) 0.001
0.55 12 (11.0) 3 (1.7) 0.001
0.46 2 (1.8) 0 (0.0) 0.07
0.46 1 (1.0) 0 (0.0) 0.20178)
)
)
)
)
)
)
)l revascularization; UFH  unfractionated heparin.
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overall event rate (9.6%) of this substudy cohort and also
below the event rate reported for the entire trial cohort (16).
In concert with the overall ISAR-REACT 4 trial results
(16), this is a strong argument for the use of bivalirudin in
NSTEMI patients who show an adequate level of P2Y12
receptor inhibition. The level of platelet inhibition achieved
in that subgroup may be an optimal level and further
inhibition, temporarily delivered with abciximab, may not
confer to further risk reduction for ischemic events. On the
other hand, the high event rate of 22% in HPR patients
(about one-third of patients) receiving adjunctive bivaliru-
din might argue for more potent P2Y12 receptor inhibitors
or additional abciximab treatment in this group of patients.
Both the third-generation thienopyridine prasugrel and the
nonthienopyridine P2Y12 receptor inhibitor ticagrelor
should be considered as a better treatment option here.
Reflecting the results of the TRITON–TIMI 38 (TRial to
assess Improvement in Therapeutic Outcomes by optimiz-
ing platelet InhibitioN with prasugrel–Thrombolysis In
Myocardial Infarction 38) (23) and the PLATO (PLATelet
inhibition and patient Outcomes) (24) trials, both drugs
(prasugrel and ticagrelor) have shown superior efficacy
profiles over clopidogrel in ACS patients in general. This is
why both agents have just recently received a class IB
indication for treatment of ACS patients, while clopidogrel
is recommended for patients who cannot receive ticagrelor
or prasugrel (10). However, the potent P2Y12 receptor
blockers are associated with a higher risk of non–coronary
artery bypass graft major bleeding (23,24). Unfortunately, in
both the TRITON–TIMI 38 and PLATO trials it was not
reported on the differential outcome of HPR and no-HPR
patients with regard to the P2Y12 receptor inhibitor used. It
may well be that specifically in ACS patients receiving
first-line clopidogrel therapy and showing HPR, the more
rapid and more potent platelet inhibition of prasugrel or
ticagrelor shows greatest benefit by reducing thrombotic risk
burden without increasing bleeding risk.
In general, an insufficient level of P2Y12 receptor inhi-
bition may warrant attention and may require its assessment
especially in situations when a coronary stenting procedure
is performed in a prothrombotic milieu, as it is the case in
ACS patients (25). Moreover, patients with an ACS/
NSTEMI are commonly treated with an early invasive
strategy, as it was also the case in ISAR-REACT 4 trial.
The often delayed (26) and commonly insufficient (27)
antiplatelet action of clopidogrel in ACS patients explains
the high rate of HPR patients (35%) observed in our study
here and may also explain the high event rate for HPR
patients within the bivalirudin study group. The contention
that bivalirudin treated ACS patients are in need of an
adequate P2Y12 receptor blocker pretreatment was also
highlighted in a post hoc analysis (28) of the HORIZONS-
AMI (Harmonizing Outcomes with Revascularization and
Stents in Acute Myocardial Infarction) trial (14). Investi-
gating the role of 2 different clopidogrel loading doses (300mg vs. 600 mg) in STEMI patients, it was shown that the
higher loading dose reduced the risk for ischemic events in
the early course after the PCI procedure (28). Thus, there is
room for further improving the outcome of bivalirudin
treated ACS patients when an optimal level of P2Y12
receptor inhibition is achieved at the time point of the
procedure. Contrariwise, administration of abciximab in a
similar setting may abate the importance of adequate clopi-
dogrel pre-treatment at the time point of the intervention
and thus diminish the relevance of HPR during the stenting
procedure. In general, the full antiplatelet action of clopi-
dogrel is not immediate in all patients and may be reached
in some patients as recently as on the day after the PCI
procedure (26). Abciximab, a potent and rapidly acting
antiaggregative agent, is able to bridge the time span of
insufficient platelet inhibition and may also dampen the
prothrombotic milieu (25) that is most pronounced around
the PCI procedure. This leaves time for patients to reach a
sufficient level of active clopidogrel metabolite generation
and when the antiplatelet action of abciximab sets off, these
patients are sufficiently inhibited via the P2Y12 receptor
pathway and the prothrombotic milieu is likely to settle step
by step in the early days after PCI. This may explain the
observation that the event rates within the abciximab plus
UFH group show a similar pattern over the entire 30-day
course and not a later separation toward higher events in the
HPR group, when the antiplatelet action of abciximab sets
off. Thus, our results do also argue for a vulnerable phase in
NSTEMI patients, directly surrounding the invasive proce-
dure, where sufficient platelet inhibition is of utmost im-
portance. Platelet function testing during this phase may
help to monitor and to guide a tailored antiplatelet treat-
ment to the needs of the individual patient.
The usefulness and possible need for routine platelet
function testing has been a topic of heated debate in recent
years (4). Studies like GRAVITAS (7) and TRIGGER-
PCI (8) aimed to assess a possible benefit of a tailored and
intensified antiplatelet treatment in HPR patients undergo-
ing coronary stenting. Both studies failed to show a benefit
of tailoring treatment on the basis of platelet function
testing. Properties of the study design, an overall low event
rate within the studies, and also the circumstance that only
low-to-intermediate risk patients were enrolled in these
studies have been put forward as possible explanations for
the negative study results. Of note, the proportion of
NSTEMI and STEMI patients was low in both
TRIGGER-PCI and GRAVITAS (7,8). Exactly NSTEMI/
STEMI patients, however, may constitute a cohort of
patients that could benefit most from platelet function
monitoring for guiding pharmacological therapy during and
after the PCI procedure. Moreover, testing may be benefi-
cial in the setting of different P2Y12 receptor blockers as
treatment with both clopidogrel (1) and prasugrel (29) is
associated with a relevant proportion of patients that con-
tinue to exhibit a status of HPR.
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against the routine use of bivalirudin in NSTEMI patients
undergoing urgent PCI. Instead, our data indicate that
there may be a differential impact of HPR during PCI,
which may depend on the choice of adjunctive antithrom-
botic treatment used. Further on, it is crucial to note that
present data are observational, stem from a post hoc analysis
of a randomized trial, and must be considered as hypothesis
generating. Therefore, further studies are warranted here
and it seems obvious to investigate this issue in the setting
of prasugrel or ticagrelor treatment, both of which now have
a Class IB recommendation for ACS patients (10). Of note,
high on-treatment platelet reactivity is also an issue with
prasugrel (29), whereas data are lacking so far for ticagrelor,
and assessing its relevance for these 2 agents in the setting
of different adjunctive antithrombotic treatment regimens
seems mandatory. Moreover, it remains unknown in how
far our findings here can be extrapolated to stable CAD
patients undergoing elective PCI. Further studies are nec-
essary to close these gaps of knowledge.
Study limitations. First, we only measured platelet func-
tion in a part of the entire study cohort of the ISAR-
REACT 4 trial. Second, we only assessed platelet function
with 1 single device (Multiplate analyzer) and at 1 pre-
specified time point during the study (directly before PCI).
Multiple measurements at different time points with differ-
ent devices would have been helpful to study the prognostic
value of clopidogrel response testing in NSTEMI patients
in more detail. Third, present results cannot be extrapolated
to prasugrel or ticagrelor treated patients and further studies
are needed here. Finally, a further limitation of the present
study is that this analysis was a post hoc analysis of a study
population that stems from a randomized trial and, there-
fore, it is subject to limitations inherent to all such analysis.
Conclusions
The impact of HPR on clinical outcomes may depend on
the type of adjunct antithrombotic therapy used during PCI.
It is more pronounced in patients treated with bivalirudin
than in those treated with UFH plus abciximab. Further
investigations are warranted to clarify whether assessment of
platelet function may help tailoring antithrombotic therapy
during PCI.
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